Inotiv, Inc. (NOTV) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, Inotiv, Inc.'s filing signal turned negative.

Inotiv, Inc. is a contract research organization (CRO) providing nonclinical and analytical drug discovery and development services, alongside selling research animals, diets, and related products. The company operates through two segments: Discovery and Safety Assessment (DSA), which offers services like bioanalytical method development, pharmacology, and toxicology testing, and Research Models and Services (RMS), which supplies purpose-bred animals, specialized models, and husbandry products. Inotiv serves a global client base, including pharmaceutical and biotechnology companies, academic institutions, and government agencies. Its services support the entire drug development lifecycle, from early discovery through preclinical and, in some cases, clinical phases, aiming to enhance efficiency and reduce costs. The company has a significant global footprint with facilities across four countries.

Revenue is driven by fees for nonclinical and analytical drug discovery and development services provided by the DSA segment, and by the sale of research-quality animals, diets, and related products through the RMS segment.